House lawmakers are raising questions about US biopharmaceutical companies that are conducting clinical trials with China’s People’s Liberation Army and in the Xinjiang region where Beijing is accused of mistreating members of the Uyghur community.
Chinese biopharmaceutical companies, with their ability to harness China’s large population of patients to conduct time- and cost-efficient clinical trials play a vital role in the global pharmaceutical industry. The lawmakers want the Food and Drug Administration to provide information about these practices.
This item is available in full to subscribers.
To continue reading, you will need to either log in to your subscriber account, below, or purchase a new subscription.
If you are a current subscriber, and had an account on our previous site, you already have an account. If you have not yet logged into our new site, click here to reset your password.
Otherwise, click here to view your options for subscribing.
Please log in to continue |